Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of AKR-001 for the treatment of patients with Type 2 diabetes

Next Previous
X
Search
Trial Profile

A phase 1 study of AKR-001 for the treatment of patients with Type 2 diabetes

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efruxifermin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics

    • Most Recent Events

    • 21 Jul 2020 According to an Akero Therapeutics media release, the data reported in this study provided the rationale for evaluating the efficacy and safety of EFX in NASH patients in Phase 2a BALANCED study.
    • 21 Jul 2020 Results presented in an Akero Therapeutics Media Release.
    • 21 Jul 2020 According to an Akero Therapeutics media release, data published in the journal Cell Reports Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top